Vicente J. Jaramillo, Meghan L. Fletcher, Toby Chiu, Preeyaporn Sarangarm
{"title":"苯巴比妥能缩短严重酒精戒断患者的住院时间吗?苯巴比妥与劳拉西泮输液的回顾性比较","authors":"Vicente J. Jaramillo, Meghan L. Fletcher, Toby Chiu, Preeyaporn Sarangarm","doi":"10.1016/j.japhar.2023.100003","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Data suggest that phenobarbital is as effective as benzodiazepines at managing withdrawal via its direct activation of the gamma-aminobutyric acid receptor and modulating glutamate-mediated stimulation of the N-methyl-D-aspartate receptor. There are little data evaluating the effect of phenobarbital on severe withdrawal syndromes.</p></div><div><h3>Objective</h3><p>The purpose of this study was to evaluate the effect of phenobarbital compared with protocolized, symptom-driven, benzodiazepine administration on hospital length of stay (LOS) in patients experiencing severe withdrawal.</p></div><div><h3>Methods</h3><p>This is a retrospective chart review of patients evaluated in the emergency department for the treatment of severe alcohol withdrawal syndrome, defined as a Clinical Institute Withdrawal Assessment for Alcohol – Revised score of 20 or greater during their visit. The primary outcome measure was the difference in hospital LOS between those receiving phenobarbital and those receiving continuous lorazepam infusions. Secondary outcomes include intensive care unit (ICU) admission, ICU LOS, need for mechanical ventilation, and incidence of oversedation.</p></div><div><h3>Results</h3><p>In all, 298 patients met inclusion, with 131 treated with phenobarbital and 167 initiated on a lorazepam infusion. Hospital LOS was found to be statistically significantly greater in the lorazepam infusion cohort (7.6 ± 5.3 vs. 5.2 ± 4.5 days, <em>P</em> < 0.001) than the phenobarbital cohort. Patients treated with lorazepam were found to have increased admissions to the ICU (risk ratio [RR] 1.79 [95% CI 1.27–2.92]) and higher rates of oversedation (RR 1.71 [95% CI 2.09–4.25]). There were no differences in ICU LOS and need for mechanical ventilation.</p></div><div><h3>Conclusion</h3><p>Data from this study suggest that phenobarbital may be associated with a decrease in hospital LOS in severe alcohol withdrawal and should be considered as an alternative to benzodiazepine infusions in these patients.</p></div>","PeriodicalId":100736,"journal":{"name":"JAPhA Pharmacotherapy","volume":"1 1","pages":"Article 100003"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949962323000037/pdfft?md5=d20c95744e78ee36c255063dec97770d&pid=1-s2.0-S2949962323000037-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Does phenobarbital reduce the hospital length of stay for patients suffering from severe alcohol withdrawal? A retrospective comparison of phenobarbital to lorazepam infusions\",\"authors\":\"Vicente J. Jaramillo, Meghan L. Fletcher, Toby Chiu, Preeyaporn Sarangarm\",\"doi\":\"10.1016/j.japhar.2023.100003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>Data suggest that phenobarbital is as effective as benzodiazepines at managing withdrawal via its direct activation of the gamma-aminobutyric acid receptor and modulating glutamate-mediated stimulation of the N-methyl-D-aspartate receptor. There are little data evaluating the effect of phenobarbital on severe withdrawal syndromes.</p></div><div><h3>Objective</h3><p>The purpose of this study was to evaluate the effect of phenobarbital compared with protocolized, symptom-driven, benzodiazepine administration on hospital length of stay (LOS) in patients experiencing severe withdrawal.</p></div><div><h3>Methods</h3><p>This is a retrospective chart review of patients evaluated in the emergency department for the treatment of severe alcohol withdrawal syndrome, defined as a Clinical Institute Withdrawal Assessment for Alcohol – Revised score of 20 or greater during their visit. The primary outcome measure was the difference in hospital LOS between those receiving phenobarbital and those receiving continuous lorazepam infusions. Secondary outcomes include intensive care unit (ICU) admission, ICU LOS, need for mechanical ventilation, and incidence of oversedation.</p></div><div><h3>Results</h3><p>In all, 298 patients met inclusion, with 131 treated with phenobarbital and 167 initiated on a lorazepam infusion. Hospital LOS was found to be statistically significantly greater in the lorazepam infusion cohort (7.6 ± 5.3 vs. 5.2 ± 4.5 days, <em>P</em> < 0.001) than the phenobarbital cohort. Patients treated with lorazepam were found to have increased admissions to the ICU (risk ratio [RR] 1.79 [95% CI 1.27–2.92]) and higher rates of oversedation (RR 1.71 [95% CI 2.09–4.25]). There were no differences in ICU LOS and need for mechanical ventilation.</p></div><div><h3>Conclusion</h3><p>Data from this study suggest that phenobarbital may be associated with a decrease in hospital LOS in severe alcohol withdrawal and should be considered as an alternative to benzodiazepine infusions in these patients.</p></div>\",\"PeriodicalId\":100736,\"journal\":{\"name\":\"JAPhA Pharmacotherapy\",\"volume\":\"1 1\",\"pages\":\"Article 100003\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2949962323000037/pdfft?md5=d20c95744e78ee36c255063dec97770d&pid=1-s2.0-S2949962323000037-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAPhA Pharmacotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2949962323000037\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAPhA Pharmacotherapy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949962323000037","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
导言:有数据表明,苯巴比妥通过直接激活γ-氨基丁酸受体和调节谷氨酸介导的N-甲基-D-天冬氨酸受体刺激,在控制戒断方面与苯二氮卓类药物一样有效。本研究的目的是评估苯巴比妥与苯二氮卓类药物在严重戒断患者住院时间(LOS)上的效果。方法这是一项回顾性病历审查,对象是在急诊科接受评估以治疗严重酒精戒断综合征的患者,严重酒精戒断综合征的定义是在就诊期间临床研究所酒精戒断评估-修订版评分达到或超过 20 分。主要研究结果是接受苯巴比妥治疗和持续输注劳拉西泮治疗的患者的住院时间差异。次要结果包括重症监护室(ICU)入院率、重症监护室住院时间、机械通气需求和过度镇静发生率。结果共有 298 名患者符合纳入条件,其中 131 人接受苯巴比妥治疗,167 人开始输注劳拉西泮。输注劳拉西泮患者的住院时间(7.6 ± 5.3 天 vs. 5.2 ± 4.5 天,P < 0.001)明显高于苯巴比妥患者。使用劳拉西泮治疗的患者入住重症监护室的次数增加(风险比 [RR] 1.79 [95% CI 1.27-2.92]),过度惊厥的发生率也更高(RR 1.71 [95% CI 2.09-4.25])。结论本研究的数据表明,苯巴比妥可缩短严重酒精戒断患者的住院时间,因此应考虑将其作为苯二氮卓类药物输注的替代方案。
Does phenobarbital reduce the hospital length of stay for patients suffering from severe alcohol withdrawal? A retrospective comparison of phenobarbital to lorazepam infusions
Introduction
Data suggest that phenobarbital is as effective as benzodiazepines at managing withdrawal via its direct activation of the gamma-aminobutyric acid receptor and modulating glutamate-mediated stimulation of the N-methyl-D-aspartate receptor. There are little data evaluating the effect of phenobarbital on severe withdrawal syndromes.
Objective
The purpose of this study was to evaluate the effect of phenobarbital compared with protocolized, symptom-driven, benzodiazepine administration on hospital length of stay (LOS) in patients experiencing severe withdrawal.
Methods
This is a retrospective chart review of patients evaluated in the emergency department for the treatment of severe alcohol withdrawal syndrome, defined as a Clinical Institute Withdrawal Assessment for Alcohol – Revised score of 20 or greater during their visit. The primary outcome measure was the difference in hospital LOS between those receiving phenobarbital and those receiving continuous lorazepam infusions. Secondary outcomes include intensive care unit (ICU) admission, ICU LOS, need for mechanical ventilation, and incidence of oversedation.
Results
In all, 298 patients met inclusion, with 131 treated with phenobarbital and 167 initiated on a lorazepam infusion. Hospital LOS was found to be statistically significantly greater in the lorazepam infusion cohort (7.6 ± 5.3 vs. 5.2 ± 4.5 days, P < 0.001) than the phenobarbital cohort. Patients treated with lorazepam were found to have increased admissions to the ICU (risk ratio [RR] 1.79 [95% CI 1.27–2.92]) and higher rates of oversedation (RR 1.71 [95% CI 2.09–4.25]). There were no differences in ICU LOS and need for mechanical ventilation.
Conclusion
Data from this study suggest that phenobarbital may be associated with a decrease in hospital LOS in severe alcohol withdrawal and should be considered as an alternative to benzodiazepine infusions in these patients.